We realized recently that the regimen described for the administration of calcineurin inhibitor for treatment of chronic graft-versushost disease (GVHD) 1 is discrepant from current practice. Previously, we used an alternate-day regimen of calcineurin inhibitor administration, 2,3 but we now administer cyclosporine or tacrolimus twice daily for treatment of chronic GVHD. Although results with the 2 regimens have not been formally compared, this change was based primarily on pharmacokinetic considerations.
No takes yet. Share an insight, caveat, or question.
Flowers et al. (2003) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: